Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives

N H Rekers; E G C Troost; C M L Zegers; W T V Germeraad; L J Dubois; P Lambin

doi:10.1016/j.canrad.2014.06.012

Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives

Cancer Radiother. 2014 Oct;18(5-6):391-5. doi: 10.1016/j.canrad.2014.06.012. Epub 2014 Aug 30.

Authors

N H Rekers¹, E G C Troost², C M L Zegers², W T V Germeraad³, L J Dubois², P Lambin²

Affiliations

¹ Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: nicolle.rekers@maastrichtuniversity.nl.
² Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
³ Department of internal medicine, GROW - School for oncology and developmental biology, Maastricht university medical centre, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.

PMID: 25179250
DOI: 10.1016/j.canrad.2014.06.012

Abstract

Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-progression. This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy.

Keywords: Immunotherapy; Immunothérapie; Radiothérapie stéréotaxique ablative; Stereotactic ablative body radiotherapy.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Bystander Effect
CTLA-4 Antigen / antagonists & inhibitors
Cell Death / immunology
Cell Death / radiation effects
Combined Modality Therapy
Dose Fractionation, Radiation
Forecasting
Humans
Immunologic Surveillance / radiation effects*
Immunotherapy*
Ipilimumab
Mice
Molecular Targeted Therapy
Neoplasm Proteins / antagonists & inhibitors
Neoplasms / immunology
Neoplasms / surgery*
Neoplasms / therapy
Neoplasms, Experimental / surgery
Neoplasms, Experimental / therapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Radiosurgery*
Randomized Controlled Trials as Topic
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
Tumor Escape / immunology
Tumor Escape / radiation effects
Tumor Necrosis Factor Receptor Superfamily, Member 9 / antagonists & inhibitors

Substances

Antibodies, Monoclonal
CTLA-4 Antigen
CTLA4 protein, human
Ipilimumab
Neoplasm Proteins
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Tumor Necrosis Factor Receptor Superfamily, Member 9